Infinity reports Phase I data for IPI-549 plus Opdivo in solid tumors

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) reported data from 30 evaluable patients with advanced solid tumors in the Phase I/Ib IPI-549-01

Read the full 193 word article

User Sign In